Hyperactivity and ID: It's not just genetics, it's O-GlcNAc dyshomeostasis

Written by The Life Science Feed Editorial Team · Published 23 September 2026 · Edited by William Lopes

Intellectual disability (ID) presents a significant clinical challenge, often linked to genetic factors that disrupt fundamental brain development and function. Recent investigations have highlighted missense variants in the O-GlcNAc transferase (OGT) gene as a cause of syndromic ID, termed OGT-ID. This discovery shows the important role of protein O-GlcNAcylation in maintaining proper brain function, yet the precise mechanisms linking OGT malfunction to the observed neurodevelopmental and neurophysiological deficits have remained largely undefined.

KEY TAKEAWAYS

- The Pivot: Pathogenic OGT variants directly cause O-GlcNAc dyshomeostasis, leading to specific cortical malformations and behavioral hyperactivity.
- The Data: Rodent models with the C921Y OGT-ID variant exhibited reduced cortical thickness, hypoplastic corpus callosum, and dysplastic changes in the neocortex.
- The Action: Clinicians should consider OGT-ID in patients presenting with syndromic intellectual disability, microcephaly, and hyperactivity, recognizing the underlying O-GlcNAc dyshomeostasis as a potential therapeutic target.

Understanding the pathophysiological mechanisms that underpin intellectual disability is important for developing targeted interventions. While OGT-ID has been identified as a syndromic form of intellectual disability linked to OGT gene variants, the specific developmental and neurophysiological consequences of OGT malfunction have been unclear. A recent study by Authier, Jan, and Faress, published in eLife, provides comprehensive analyses of a rodent model carrying a pathogenic OGT-ID variant, shedding light on these important mechanisms.1

The investigators developed a rodent model carrying the C921Y OGT-ID variant, a specific missense mutation previously identified in human patients with OGT-ID. They subjected these mice to a battery of behavioral assessments and detailed structural and histological brain analyses. This approach allowed for a direct correlation between the genetic variant, the resulting O-GlcNAc dyshomeostasis, and the observed neurodevelopmental and behavioral phenotypes. The study aimed to delineate whether OGT malfunction primarily affects brain development, neurophysiology, or a combination of both, providing a platform for future therapeutic exploration.1

Behavioral and Structural Phenotypes in OGT-ID Models

The rodent model carrying the C921Y OGT-ID variant displayed a distinct range of behavioral deficits, indicating significant neurophysiological perturbations. These mice exhibited pronounced hyperactivity, a common feature

in various neurodevelopmental disorders, alongside impulsivity. The researchers quantified these behaviors using established paradigms, observing consistent patterns across the cohort. This hyperactivity was not merely anecdotal; it was a measurable and reproducible phenotype, suggesting a fundamental disruption in neural circuits governing motor control and inhibitory responses.1

Beyond hyperactivity, the OGT-ID variant mice also showed deficits in associative learning. This impairment points to broader cognitive dysfunction, extending beyond simple motor control. Associative learning is a complex process involving multiple brain regions, including the hippocampus and prefrontal cortex, and its disruption suggests widespread impact on neural plasticity and memory formation. These behavioral findings collectively paint a picture of significant neurological impairment, mirroring aspects of human intellectual disability.1

Structural analyses of the brains of these OGT-ID variant mice revealed profound developmental abnormalities. Micro-computed tomography and magnetic resonance imaging (MRI) consistently demonstrated a reduced skull size and overt microcephaly. Microcephaly, characterized by an abnormally small head, is a strong indicator of impaired brain growth and is frequently associated with intellectual disability in humans. The presence of microcephaly in this model provides a clear anatomical correlate to the observed cognitive and behavioral deficits.1

Further detailed imaging revealed specific structural defects within the brain itself. The OGT-ID variant mice had reduced cortical thickness, a critical measure of brain development and neuronal density. The cerebral cortex is responsible for higher-order functions, and its thinning suggests a compromised capacity for complex processing. The corpus callosum, a major white matter tract connecting the two cerebral hemispheres, was hypoplastic. A hypoplastic corpus callosum implies impaired interhemispheric communication, which can contribute to a wide range of neurological symptoms, including learning difficulties and motor coordination problems. These structural changes are not subtle; they represent significant deviations from normal brain architecture.1

Histological and Mechanistic Insights into Cortical Dysplasia

Detailed histological analyses provided a microscopic view of the dysplastic changes occurring in the neocortex of the OGT-ID variant mice. These changes predominantly affected the superficial layers of the cingulate cortex. Cortical dysplasia refers to an abnormal organization of neurons in the cerebral cortex, often characterized by abnormal neuronal migration, lamination, and cellular morphology. Such dysplastic changes are well-known to be epileptogenic and can lead to severe neurological impairments, including intellectual disability and seizures. The specific involvement of superficial layers suggests a disruption in later stages of cortical development, which are essential for establishing complex cortical circuits.1

The cingulate cortex, a key component of the limbic system, plays a vital role in emotion, learning, and memory. Dysplastic changes in this region could directly contribute to the observed behavioral phenotypes, such as impulsivity and associative learning deficits. The precision of these histological findings allows for a more targeted investigation into the cellular and molecular underpinnings of OGT-ID. It moves beyond broad structural abnormalities to pinpoint specific regions and cellular layers affected by O-GlcNAc dyshomeostasis.1

Mechanistically, quantitative proteomic analyses were performed to understand the molecular consequences of the C921Y OGT-ID variant. These analyses confirmed O-GlcNAc dyshomeostasis, meaning an imbalance in the levels of O-GlcNAcylation on various proteins. O-GlcNAcylation is a dynamic post-translational modification that regulates protein function, stability, and localization, playing an important role in cellular signaling and gene expression. The

dyshomeostasis observed here indicates that the pathogenic OGT variant directly impairs the proper regulation of this vital modification.1

The proteomic data further revealed that this O-GlcNAc dyshomeostasis was associated with distinct perturbed molecular pathways involved in brain development. These pathways include those responsible for neuronal migration, differentiation, synaptogenesis, and axonal guidance. Disruption of these fundamental developmental processes can explain the observed cortical malformations, reduced cortical thickness, and hypoplastic corpus callosum. The study effectively links the genetic mutation to a molecular imbalance, which then cascades into specific developmental defects and ultimately, behavioral phenotypes. This mechanistic understanding is a critical step towards identifying potential therapeutic targets. The complex relationship of molecular pathways in brain health continues to be a focus of intense research.

Implications for Neurodevelopmental Disorders and Future Directions

The data from this rodent model clearly reveal neurodevelopmental defects directly associated with O-GlcNAc dyshomeostasis. This provides a compelling platform for dissecting the precise mechanisms underlying OGT-ID. Understanding that OGT malfunction leads to specific structural and functional brain abnormalities offers new avenues for research into the pathogenesis of intellectual disability. It suggests that restoring O-GlcNAc homeostasis could be a viable therapeutic strategy.1

The study's findings have broader implications for other neurodevelopmental disorders where O-GlcNAcylation might be implicated. Many genetic syndromes present with similar phenotypes of intellectual disability, microcephaly, and behavioral issues. Investigating O-GlcNAc status in these conditions could uncover shared pathogenic mechanisms. For instance, the management of other developmental malformations often benefits from a deeper understanding of underlying molecular pathways.

But the study was conducted in a rodent model, and while these models are invaluable for mechanistic studies, translating findings directly to human patients always presents challenges. The C921Y variant is a specific mutation, and other OGT variants might lead to different phenotypes or milder forms of dyshomeostasis. The long-term consequences of these developmental defects in the rodent model, particularly into adulthood, were not fully explored, leaving questions about the progressive nature of OGT-ID. Still, the detailed structural and behavioral phenotyping provides a robust foundation for future translational research. Clinicians managing patients with syndromic ID and microcephaly might consider genetic testing for OGT variants, especially when hyperactivity is a prominent feature. For a comprehensive overview of neurological disorders, the Oxford Handbook of Neurology remains an invaluable resource.

The study did not investigate potential therapeutic interventions, focusing instead on establishing the pathogenic link. This is a critical first step, but the ultimate goal is to develop treatments. Future research will need to explore whether pharmacological or genetic interventions aimed at modulating O-GlcNAc levels can ameliorate the observed developmental defects and behavioral phenotypes. This could involve targeting OGT activity directly or indirectly influencing the O-GlcNAc cycling enzymes. The precise timing of such interventions during development will also be important for therapeutic success, given the neurodevelopmental nature of the pathology. The intersection of genetic predispositions and neurological outcomes is an area of rapid advancement.

The open-label nature of the proteomic analysis is an obvious caveat, as is typical for discovery-phase mechanistic studies. While quantitative, the interpretation of perturbed pathways relies on existing knowledge bases, which may

not capture all novel interactions. The study was not powered to detect subtle differences in O-GlcNAc levels across all brain regions, focusing instead on global dyshomeostasis and specific protein targets. This leaves room for more granular regional analyses in future work. The investigators also did not explore the potential for environmental factors to modulate the expression of these phenotypes, which could be relevant for human patients. Understanding the full spectrum of OGT-ID will require further investigation into genetic modifiers and environmental influences. The link between traumatic brain injury and psychiatric conditions highlights the complexity of brain health.

CLINICAL IMPLICATIONS

This research provides a clear mechanistic link between OGT gene variants and specific neurodevelopmental defects, offering a more precise understanding of OGT-ID. For clinicians encountering patients with syndromic intellectual disability, microcephaly, and pronounced hyperactivity, this study suggests that OGT-ID should be a consideration in the differential diagnosis. Early genetic screening for OGT variants could become more routine, particularly as our understanding of O-GlcNAc dyshomeostasis as a pathogenic driver solidifies.

The identification of O-GlcNAc dyshomeostasis as the underlying molecular pathology opens avenues for targeted therapeutic development. While direct OGT modulators are not yet in clinical practice for this indication, this mechanistic clarity provides a foundation for pharmaceutical companies to explore interventions that restore O-GlcNAc balance. This could involve small molecules that enhance OGT activity or inhibit O-GlcNAcase, the enzyme that removes O-GlcNAc, thereby re-establishing cellular homeostasis.

Patients and their families often face significant diagnostic odysseys when dealing with rare genetic disorders. A clearer understanding of OGT-ID's pathophysiology can streamline diagnosis and provide a more concrete explanation for the observed symptoms. This knowledge empowers families, offering hope for future targeted therapies and improved management strategies, moving beyond symptomatic treatment to address the root cause of the disorder.

But the translation from rodent models to human clinical benefit is rarely straightforward. The precise window for therapeutic intervention during brain development will be critical, and the long-term safety and efficacy of any O-GlcNAc modulating therapies will require rigorous clinical trials. Still, this work provides a solid biological rationale for pursuing such interventions, offering a tangible target in a field often characterized by symptomatic management.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Authier F, Jan A, Faress I. Pathogenic O-GlcNAc dyshomeostasis is associated with cortical malformations and hyperactivity. Elife. 2026;15:e42770280.

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com